Fortrea says China regulatory reforms speed rare disease drug development, support earlier global trials
Fortrea published an industry analysis arguing that China’s regulatory reforms are accelerating rare-disease drug development and making the country easier to integrate into global clinical programs. The report highlights China’s 2017 entry into the ICH as a turning point that supports earlier inclusion in multi-region